Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates

DOI10.1111/J.1541-0420.2008.01009.XMaRDI QIDQ3549405zbMATH OpenOpenAlexWikidataFDO

Authors Peter F. Thall, Hoang Q. Nguyen, Elihu H. Estey

Publication date 22 December 2008

Published in Biometrics (Search for Journal in Brave)

Full work available at URL https://doi.org/10.1111/j.1541-0420.2008.01009.x

zbMATH Keywords

Bayesian designphase I clinical trialadaptive designphase I/II clinical trialbiologic agentsindividualized treatment

Mathematics Subject Classification ID

Bayesian inference (62F15) Applications of statistics to biology and medical sciences; meta analysis (62P10) Sequential statistical design (62L05)

Recommendations

• Patient-specific dose finding in phase I clinical trials
• A New Dose‐Finding Design for Bivariate Outcomes
• Patient-specific dose finding in seamless phase I/II clinical trials
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• A utility approach to individualized optimal dose selection using biomarkers
• A parsimonious personalized dose-finding model via dimension reduction
• A dose finding procedure based on the multivariate likelihood ratio test
• Clinical trials for personalized dose finding
• Dose-finding with two agents in phase I oncology trials

Cites work

• scientific article; zbMATH DE number 1350773 (Why is no real title available?)
• scientific article; zbMATH DE number 1134711 (Why is no real title available?)
• scientific article; zbMATH DE number 2242805 (Why is no real title available?)
• A Geometric Approach to Comparing Treatments for Rapidly Fatal Diseases
• A New Dose‐Finding Design for Bivariate Outcomes
• Bayesian Measures of Model Complexity and Fit
• Continual reassessment method for ordered groups
• Correlated Binary Regression with Covariates Specific to Each Binary Observation
• Dose-Finding Based on Efficacy-Toxicity Trade-Offs
• Dose-Response Models with Covariates
• Dose-finding designs for HIV studies
• TWO-SAMPLE CONTINUAL REASSESSMENT METHOD

Cited in

(17)

• Individualized dosing for multiple ordered groups of patients
• Bayesian models and decision algorithms for complex early phase clinical trials
• Patient-specific dose finding in phase I clinical trials
• Patient-specific dose finding in seamless phase I/II clinical trials
• Adaptive isotonic estimation of the minimum effective and peak doses in the presence of covariates
• Optimizing the concentration and bolus of a drug delivered by continuous infusion
• Utility-Based Optimization of Combination Therapy Using Ordinal Toxicity and Efficacy in Phase I/II Trials
• A utility approach to individualized optimal dose selection using biomarkers
• Learning optimal personalized treatment rules in consideration of benefit and risk: with an application to treating type 2 diabetes patients with insulin therapies
• Pharmacokinetically guided optimum adaptive dose selection in early phase clinical trials
• Risk-group-specific dose finding based on an average toxicity score
• Estimating individualized treatment rules with risk constraint
• Clinical trials for personalized dose finding
• Bayesian adaptive design of early-phase clinical trials for precision medicine based on cancer biomarkers
• Adaptive Bayesian compound designs for dose finding studies
• Bayesian learning of dose-response parameters from a cohort under response-guided dosing
• A Bayesian adaptive phase I/II clinical trial design with late‐onset competing risk outcomes

This page was built for publication: Patient‐Specific Dose Finding Based on Bivariate Outcomes and Covariates

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q3549405)